Test Price
2,800 AED✅ Home Collection Available
IL12B Gene Psoriasis Susceptibility Type 11 Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited processing using Next Generation Sequencing (NGS) on the Illumina® platform for complete IL12B gene coverage.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM, staffed by DHA-licensed phlebotomists.
- Clinical Guidance: Telephonic post-test consultation with a board-certified genetic counselor to interpret your personalized risk score and discuss preventive strategies.
- Insurance: Direct billing verification via WhatsApp at +971 54 548 8731 with select UAE health insurance providers.
Test Overview & Methodology
The IL12B Gene Psoriasis Susceptibility Type 11 Genetic Test detects pathogenic single-nucleotide variants and small insertions/deletions in the IL12B gene, which encodes the p40 subunit of interleukin-12 and interleukin-23. Specific IL12B polymorphisms are strongly associated with increased susceptibility to psoriasis, particularly type 11 (early-onset, familial clustering). This NGS-based assay enables personalized risk stratification, informs first-degree relative screening decisions, and guides targeted biologic therapy selection such as ustekinumab, which directly inhibits the IL-12/IL-23 pathway.
| Feature | Our Test (NGS) | Closest Alternative |
|---|---|---|
| Precision | 99.9% analytical sensitivity; full gene coding regions and splice sites | Targeted genotyping with limited variant detection coverage |
| Method | Next Generation Sequencing (Illumina®) with bidirectional Sanger confirmation | PCR-RFLP or Sanger sequencing only |
| Speed (TAT) | 3 to 4 weeks | 4 to 6 weeks |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA Registration ID: 9294403), notes: "A positive IL12B variant result indicates an elevated genetic susceptibility to psoriasis, not a guaranteed diagnosis. Clinical correlation with a dermatologist and pre- and post-test genetic counselling are essential to interpret findings within your personal and family history. This test empowers proactive dermatology surveillance and may inform therapeutic decisions, but it must never replace a comprehensive clinical evaluation. Our multidisciplinary team is committed to guiding you through every step with clarity and compassion."
Advisory: Do Not Discontinue Prescribed Therapy
Never stop or alter any prescribed psoriasis medication — including systemic immunosuppressants or biologic agents — without explicit instruction from your treating physician. This genetic test is a risk assessment tool and does not replace ongoing clinical management.
Exclusion Criteria & Red Flags
- Inability to provide informed consent; minors without legal guardian consent per Federal Law No. 2 of 2019 and PDPL regulations.
- Acute psychiatric distress or active suicidal ideation requiring immediate crisis intervention.
- Known coagulopathy that prevents safe phlebotomy — an alternative FTA card or extracted DNA sample may be accepted after clinical review.
- If you develop severe skin inflammation, joint pain, or any medical emergency, seek immediate care at the nearest emergency department. This test does not replace urgent medical management.
Patient FAQ & Clinical Guidance
1. What specific information will this IL12B gene test provide about my psoriasis risk?
Key Insight: The test identifies defined pathogenic and risk-conferring variants in the IL12B gene that are statistically linked to psoriasis type 11 susceptibility. Your report will include a clear classification of each variant (pathogenic, likely pathogenic, or risk allele) along with an evidence-based interpretation of your lifetime risk profile, enabling informed discussions with your dermatologist and genetic counsellor.
2. How should I prepare for the sample collection, and what type of specimen is needed?
Key Insight: No fasting or special preparation is required. A DHA-licensed phlebotomist will collect a standard peripheral whole blood sample (2–4 mL in an EDTA tube) at your preferred location via our VIP Mobile Phlebotomy service between 8 AM and 11 PM. Alternatively, a DNA sample from a buccal swab or archival blood specimen may be accepted after prior laboratory approval. Pre-test genetic counselling is scheduled before collection to ensure informed consent.
3. When will I receive my results, and how will they be explained to me?
Key Insight: Results are typically available within 3 to 4 weeks from sample receipt. A dedicated genetic counsellor will schedule a telephonic consultation to walk you through your report, explain your personalized risk classification, clarify implications for family members, and provide tailored recommendations for surveillance or preventive measures. A written clinical report is also delivered electronically and by postal mail.
UAE Regulatory & Data Privacy Adherence
This genetic test and all associated data processing operations strictly comply with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. All laboratory processes are ISO 9001:2015 certified (Cert. No. INT/EGQ/2509DA/3139). Your genetic data is encrypted, access-controlled, and never shared with third parties without your explicit written consent. You retain the right to access, rectify, and request deletion of your data under PDPL Articles 14 and 15.
Clinical & Logistical Metadata
| Test Name | IL12B Gene Psoriasis Susceptibility Type 11 Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 weeks from sample receipt |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA) or extracted DNA specimen; VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily 8 AM – 11 PM |
| Methodology Used | Next Generation Sequencing (Illumina®) with bidirectional Sanger confirmation of clinically significant variants |
| ICD-10-CM Code | L40.0 (Psoriasis vulgaris) |
| LOINC Code | 98171-3 (IL12B gene mutation analysis) |
| DHA Facility License & Address | DHA Facility License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians